# Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

> **NCT06290934** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 228 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** emvistegrast
- **DRUG:** Placebo-to-match emvistegrast

## Key facts

- **NCT ID:** NCT06290934
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2026-03-04
- **Final completion:** 2028-04
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06290934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06290934, "Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06290934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*